Skip to content

MDMA‐assisted therapy for PTSD reduced symptoms in Phase 3 trial

The Brown University Psychopharmacology Update 2024 DOI: 10.1002/pu.31105 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Population People with post-traumatic stress disorder
Duration 3 months
Topics MDMA PTSD
Key findings MDMA-assisted therapy significantly improved PTSD symptoms and functional impairment compared with placebo plus therapy.

Abstract

Three sessions of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted therapy over 3 months significantly improved symptoms of post‐traumatic stress disorder (PTSD) compared with placebo plus therapy in a Phase 3 trial. MDMA‐assisted therapy also resulted in improvement in a measure of functional impairment. Study results were published online Sept. 14, 2023, in Nature Medicine.

Related reading